ENA Respiratory Secures Key U.S. Patent Allowances for TLR2 Agonist INNA-051, Strengthening COPD Exacerbation Franchise
核心洞察
ENA Respiratory (搜索) received USPTO Notices of Allowance for a composition-of-matter patent and a method-of-use patent covering its lead candidate INNA-051, a TLR2 (搜索)/6 agonist.
The method-of-use patent specifically protects INNA-051 for preventing rhinovirus (搜索)-mediated exacerbations of COPD, a condition with no approved antiviral or vaccine.
The strengthened IP portfolio now includes 55 granted patents and allowed applications across major global markets, with potential exclusivity extending to at least 2042.
Melbourne-based ENA Respiratory (搜索) has fortified its intellectual property position with Notices of Allowance from the U.S. Patent and Trademark Office for two patent applications central to its lead drug candidate, INNA-051. The allowances cover a composition-of-matter patent (US 17/622,451) for its Toll-like receptor 2 (TLR2 (搜索)) agonist platform and a method-of-use patent (US 16/495,829) specifically protecting the prevention of rhinovirus (搜索)-mediated exacerbations in patients with chronic obstructive pulmonary disease (搜索) (COPD). This dual milestone transforms INNA-051 from a promising clinical asset into a defensible commercial product with a clear regulatory pathway.
A Fortified IP Moat
The composition-of-matter patent represents the broadest form of pharmaceutical protection, safeguarding the molecular structure of ENA Respiratory (搜索)'s TLR2 (搜索) agonist compounds and preventing competitors from developing structurally similar molecules. The method-of-use patent carves out a targeted commercial niche: preventing COPD flare-ups triggered by rhinovirus (搜索) infection, the most commonly identified viral trigger of acute exacerbations.
These allowances expand the company's IP estate to 55 granted patents and allowed applications spanning the United States, Europe, the United Kingdom, Japan, and China. The portfolio encompasses seven distinct patent families with claims covering the composition of matter for INNA-051, backup molecules, formulations, and method-of-use protections. An additional 39 applications remain pending across various jurisdictions.
Christophe Demaison, PhD, CEO of ENA Respiratory (搜索), emphasized the commercial significance: "These allowances further strengthen a portfolio that already provides broad protection for our INNA-051 program with potential exclusivity for INNA-051 out to at least 2042 and likely beyond." That timeline provides a substantial runway for market penetration and return on investment, enhancing the company's attractiveness for licensing, collaboration, or acquisition.
A Virus-Agnostic Mechanism
INNA-051 is not a conventional antiviral or vaccine. It is a host-directed innate immune modulator—a potent agonist of TLR2 (搜索)/6—administered as a once-weekly dry powder nasal spray. By priming the body's first-line immune defenses in the upper respiratory tract, the drug enables rapid neutralization of invading viruses before they establish serious infection. This virus-agnostic approach has demonstrated preclinical efficacy against influenza, RSV, and coronaviruses, including SARS-CoV-2, positioning INNA-051 as a potential tool for both seasonal protection and pandemic preparedness.
The company's backing from the Gates Foundation, Flu Lab, and the U.S. Government's BLUE KNIGHT initiative—a partnership between BARDA and Johnson & Johnson Innovation—underscores its perceived strategic importance in global health security.
Addressing the COPD Exacerbation Crisis
The method-of-use patent targets a well-defined and urgent unmet medical need. Rhinovirus (搜索) is the predominant viral trigger of Acute Exacerbations of COPD (AECOPD), the primary driver of COPD morbidity and mortality. Respiratory viral infections are associated with up to 64% of exacerbation events, with rhinovirus accounting for the majority of virus-positive cases. Despite this burden, no licensed vaccine or antiviral against rhinovirus exists.
In the United States alone, COPD accounts for approximately 854,000 emergency department visits, over 335,000 hospitalizations, and approximately 142,000 deaths annually. INNA-051 aims to provide prophylactic protection, reducing the frequency and severity of exacerbations by preventing initial viral infection from escalating. The company's partnership with the U.S. COPD Foundation supports patient-focused clinical development aligned with real-world needs.
Clinical Progress and Strategic Capital
ENA Respiratory (搜索) is advancing its Phase IIa 'POSITS' study (NCT07222670) in the United States, evaluating the safety, tolerability, and efficacy of once-weekly INNA-051 administered as a dry powder nasal spray. The study assesses the drug's impact on the incidence, duration, and severity of symptomatic infections caused by common respiratory viruses—including influenza, RSV, rhinovirus (搜索), and coronaviruses—in young adult participants at risk due to living or working in crowded environments. The first part of the study, involving 200 participants, has been completed with no safety concerns reported, and recruitment for the larger second part is set to resume in August 2026, targeting a total of 1,100 participants.
The company is funded by a syndicate of investors including Brandon Capital, the Minderoo Foundation, Stoic Venture Capital, and Uniseed, alongside contracts from the U.S. Department of Defense, suggesting potential applications in protecting military personnel and first responders.